Company / Free Cash Flow
Abbott Laboratories Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$7.4B
FY2025
5-year range
$4.5B / $8.6B
FY2021-FY2025
Trend
+16.4%
vs FY2024
Sector context
#4 of 151
Health Care
What the data says
Among 151 Health Care companies, Abbott Laboratories is in the top 3% for free cash flow. Free Cash Flow has fluctuated over the past 10 years, ranging from $1.9B in FY2017 to $8.6B in FY2023.
Based on SEC 10-K filings.
$7.4B in FY2025 with a 5-year CAGR of +8.6%. Top quartile in the Health Care sector.
Declined from $8.6B to $7.4B over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- +8.9%
- 5-Year CAGR
- +8.6%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 151This company $7.4B Sector average $779.8M
▼
+848.3% above sector average
Key checks
Key Insights
- 5-year CAGR of +8.6%, indicating consistent growth.
- In FY2025, free cash flow increased 16.4% year-over-year.
- Ranks #4 out of 151 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2023.
Company context
Key Data Points
- Strong profit margin: 31.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 27.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.4B | +16.4% |
| FY2024 | $6.4B | -26.6% |
| FY2023 | $8.6B | +51.1% |
| FY2022 | $5.7B | +27.3% |
| FY2021 | $4.5B | -8.3% |
| FY2020 | $4.9B | +9.1% |
| FY2019 | $4.5B | +116.0% |
| FY2018 | $2.1B | +12.2% |
| FY2017 | $1.9B | -28.6% |
| FY2016 | $2.6B | +19.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026